Genomtec S.A.

Warsaw Stock Exchange GMT.WA

Genomtec S.A. Current Liabilities for the year ending December 31, 2023: USD 797.29 K

Genomtec S.A. Current Liabilities is USD 797.29 K for the year ending December 31, 2023, a 50.31% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Genomtec S.A. Current Liabilities for the year ending December 31, 2022 was USD 530.43 K, a -16.47% change year over year.
  • Genomtec S.A. Current Liabilities for the year ending December 31, 2021 was USD 635.02 K, a 113.68% change year over year.
  • Genomtec S.A. Current Liabilities for the year ending December 31, 2020 was USD 297.18 K, a -2.78% change year over year.
  • Genomtec S.A. Current Liabilities for the year ending December 31, 2019 was USD 305.67 K.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
SV Wall Street
Warsaw Stock Exchange: GMT.WA

Genomtec S.A.

CEO Mr. Miron Tokarski Ph.D.
IPO Date March 17, 2021
Location Poland
Headquarters Bierutowska Street 57-59
Employees 17
Sector Healthcare
Industries
Biotechnology Medical Instruments
Description

Genomtec S.A. researches, develops, manufactures, and commercializes innovative molecular diagnostic products in optical systems and isothermal nucleic acid amplification methods in Poland and internationally. The company develops Genomtec ID, a technological device that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analyzing the biological material of patients using swabs, urine samples, saliva, blood, and other body fluids. It also develops Genomtec Tumor, a SNAAT based solution used to identify neoplastic mutations and mutations with prognostic value in neoplastic disease; Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit to detect SARS-CoV-2 RNA in various biological samples from patients with suspected COVID-19 infection; and Genomtec RT-LAMP CE-IVD Duo-Kit for the detection of all variants of the SARS-CoV-2 virus. Genomtec S.A was founded in 2016 and is based in Wroclaw, Poland.

StockViz Staff

February 8, 2025

Any question? Send us an email